Cargando…

A positive feed-forward loop between Fusobacteriumnucleatum and ethanol metabolism reprogramming drives laryngeal cancer progression and metastasis

Alcohol consumption, which affects the structure and composition of the laryngeal microbiota, is one of the most important risk factors for laryngeal squamous cell cancer (LSCC). Our results demonstrated that high enrichment of Fusobacterium nucleatum (F. nucleatum) in LSCC was associated with poor...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsueh, Chi-Yao, Huang, Qiang, Gong, Hongli, Shen, Yujie, Sun, Ji, Lau, Hui-Ching, Zhang, Duo, Tang, Di, Wu, Chunping, Guo, Yang, Huang, Huiying, Cao, Pengyu, Tao, Lei, Zhang, Ming, Zhou, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851092/
https://www.ncbi.nlm.nih.gov/pubmed/35198889
http://dx.doi.org/10.1016/j.isci.2022.103829
Descripción
Sumario:Alcohol consumption, which affects the structure and composition of the laryngeal microbiota, is one of the most important risk factors for laryngeal squamous cell cancer (LSCC). Our results demonstrated that high enrichment of Fusobacterium nucleatum (F. nucleatum) in LSCC was associated with poor prognosis. F. nucleatum increased miR-155-5p and miR-205-5p expression to suppress alcohol dehydrogenase 1B (ADH1B) and transforming growth factor β receptor 2 (TGFBR2) expression by activating innate immune signaling, resulting in ethanol metabolism reprogramming to allow F. nucleatum accumulation and PI3K/AKT signaling pathway activation to promote epithelial-mesenchymal transition, further exacerbating the uncontrolled progression and metastasis of LSCC. Therefore, the positive feed-forward loop between F. nucleatum and ethanol metabolism reprogramming promotes cell proliferation, migration, and invasion to affect LSCC patient prognosis. The amount of F. nucleatum is a potential prognostic biomarker, which yields valuable insight into clinical management that may improve the oncologic outcome of patients with LSCC.